FOLFOX和FOLFOXIRI方案在结直肠癌肝转移术后患者中的应用
DOI: 10.3971/j.issn.1000-8578.2015.11.019
Keywords: 结直肠肿瘤,奥沙利铂,伊立替康,辅助化疗,Effect of Neoadjuvant Chemotherapy Cycles on Pathologic Complete Response Rate Under Different Estrogen Receptor Status of Breast Cancer,UGCG is Involved in Oxaliplatin Resistance Mechanism of Human Colon Cancer Through Regulating MDR1/P-gp Expression,Efficacy and Safety of Weekly Liposome-paclitaxel or Oxaliplatin Combined with Tegafur on Elderly Advanced Gastric Cancer,Effects of Different Doses of Bevacizumab on Irinotecan Distribution in Nude Mice Bearing Human Colon Cancer Cell Xenografts,Research Progress of Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma,Valuation of SUVmax, Ki-67, p53 and EGFR in Predicting Effect of Neoadjuvant Chemotherapy on Triple-negative Breast Cancer Patients,Platinum Resistance after Neoadjuvant Chemotherapy Interval Debulking Surgery Compared with Primary Debulking Surgery on Patients with Advanced Epithelial Ovarian Carcinoma,Tumor-infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma,原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性,Concurrent IMRT Hyperfraction Radiochemotherapy Combined with Adjuvant Chemotherapy on Elderly Patients with Locally Advanced Esophageal Cancer,Tanshinone ⅡA Inhibits Nerve Growth Factor Expression in Rats with Oxaliplatininduced Peripheral Neuropathy,Effect of Oxaliplatin on CD44V6, VEGF, survivin, Caspase-3 and Caspase-7 in Dimethylhydrazine-induced Colon Cancer Rats,Comparison of Efficacy and Prognosis of Oxaliplatin-based Regimens and FOLFIRI Regimen as First-line Chemotherapy for Stage Ⅳ Colorectal Cancer Patients with Different K-ras Statuses,Curative Effect of DOF Combined with Thalidomide Regimen and DOF Regimen Alone as First-line Treatment for Advanced Gastric Cancer,Therapeutic Effect of Raltitrexed or Fluorouracil plus Irinotecan as Second-line#br# Treatment for Advanced Colorectal Cancer
Abstract:
摘要 目的 比较FOLFOXIRI（folinic acid, 5-fluorouracil, oxaliplatin and irinotecan）和FOLFOX（folinic acid, 5-fluorouracil and oxaliplatin）两种化疗方案在肠癌肝转移同期手术切除患者中的有效性及安全性。方法 回顾性分析2008年1月至2011年7月结直肠癌伴肝转移同期手术切除患者60例，分为两组，分别接受FOLFOXIRI或FOLFOX两种化疗方案，观察不良反应以及1、2、3年无病生存期（DFS）和总生存期（OS），采用Kaplan-Merier进行生存分析。结果 接受FOLFOXIRI或FOLFOX两种化疗方案的60例患者，不良反应包括白细胞下降、血小板下降、贫血、恶心呕吐、腹泻、肝肾功能损害、神经毒性、口腔黏膜炎、脱发，FOLFOXIRI组在白细胞减少及腹泻方面有更高的不良事件发生率，其余不良反应与FOLFOX组相仿。两组患者1、2、3年无病生存率分别为73.3%、43.3%、26.7%和60%、13.3%、10%，其中2、3年DFS存在统计学差异。两组患者1、2、3年总生存率分别为86.7%、73.3%、36.7%和83.3%、50%、13.3%，其中3年OS差异有统计学意义（P=0.024）。结论 FOLFOXIRI和FOLFOX两种化疗方案安全有效，FOLFOXIRI组在白细胞减少及腹泻方面有更高的不良事件发生率，但更具远期生存优势
Full-Text
